65,437 trials
Inflammation · Pain · Cataract
Primary: Proportion of Subjects With Clearing of Anterior Inflammation — 18; 18; 13 Participants
Glabellar Frown Lines
Primary: The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year — 148 Participants
Glabellar Frown Lines
Primary: The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year — 235 Participants
Dysfunctional Voiding · Postoperative Pain
Primary: Percentage of Participants With a Failed Voiding Trial — 35; 32; 9; 12 Participants
Highly Drug-resistant Focal Epilepsy
Primary: 75 % Responder Rate During the 2-week Inpatient Period — 11.1; 30.8 percentage of participants — p==0.0679
Pulmonary Hypertension
Primary: Changes in RV Function — 7.56 percentage
Cerebral Palsy
Primary: Frequency of In-person Health Care Encounters — 24; 19; 41; 46 days
Pain Management · Anxiety
Primary: Change in Pain — 1.55; 1.76 score on a scale
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Pulmonary Arterial Hypertension
Primary: Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil — 8170; 8390; 15200; 4550…
Metastatic Castration-Resistant Prostate Cancer
Primary: Number of Participants With Adverse Events (AEs) — 60; 56; 58; 16 Participants
Thyroid Neoplasm · Goiter
Primary: To Compare the Amount of Post-operative Wound Drainage Between the Group of Patients in Which EVICEL™ Spray is Utilized (Arm A), and the Group of Patients in Which an…
Jaundice, Neonatal
Primary: Safety of Phototherapy — 268; 325 treatment days
Acne Vulgaris
Primary: Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 — -14.5; -13.5 Lesions — p=0.3430
Uterine Leiomyoma · Uterine Fibroids
Primary: Number of Adverse Events — 77; 75 Adverse Events